Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly

Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene 
and Eli Lilly 
NEW YORK, NY -- (Marketwired) -- 02/24/14 --  Lincoln Park Capital
(LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB:
NVLX) in exchange for an initial $2 million out of what can be viewed
as a $27 million "pot of money" to advance the company's late-phase
pancreatic cancer clinical trials. Notice we said restricted shares,
that's right, LPC has put a great deal of its money on the line with
a number of built in protections for Nuvilex. But, is this investment
really a risk? It appears the Chicago-based firm knows exactly what
the future could hold for Nuvilex, and they're comfortable with
paying a premium price to become a long-term investor right along
with many others who believe in the small biotechnology firm.  
Much like its investment with Elite Pharmaceuticals in April 2013
that has since seen that company's price per share rise to highs of
over 500%, LPC could benefit greatly from a much higher price tag
when Nuvilex enters late-phase clinical trials, completes those
trials and applies for approval with the FDA.  
LPC has at least two members of its team, Dr. Michael Beaubaire and
Jonathan Cope, who are biotech savvy and have clearly seen the
results from two previous independent Phase II clinical trials using
the pancreatic cancer treatment that combines Cell-in-a-Box(TM)
live-cell encapsulation with the anti-cancer drug ifosfamide - a
treatment recently licensed by Nuvilex. Those results indicated that
this combination treatment outperformed Eli Lilly's long-time
single-agent treatment for advanced inoperable pancreatic cancer,
Gemzar(R) (gemcitabine), and Celgene's recently approved drug
Abraxane (a nanoparticle formulation of the widely used drug Taxol
with albumin) in combination with gemcitabine. 
Results from the Cell-in-a-Box-ifosfamide combination in patients
with advanced pancreatic cancer included almost a doubling of median
survival time from 5.7 months for Gemzar to the 11 months seen with
the combination; this compares to the 8.5 months seen with the
Abraxane-gemcitabine combination. The results also included a 100%
increase in the one-year survival rate as compared to gemcitabine
versus a 59% increase for the Abraxane-gemcitabine combination.  
The results obtained with the Cell-in-a-Box-ifosfamide combination
are even more noteworthy given that only one-third of the dose of
ifosfamide normally used to treat other types of cancer was used in
the Phase II pancreatic cancer trials. It is likely that this lower
dosage also contributed to the fact that there were no significant
side effects from the Cell-in-a-Box-ifosfamide combination. However,
there were significant and severe drug-associated toxicities seen
with both single-agent Gemzar and with the Abraxane-gemcitabine
LPC realizes that if these results can be repeated in Nuvilex's
planned late-phase clinical trials, then the FDA approved treatments
developed by biopharmaceutical giants Celgene and Eli Lilly will
surely be unseated as the "gold standard" treatment for advanced
inoperable pancreatic cancer. Keep in mind Eli Lilly has parlayed
gemcitabine into more than $10 billion.  
Nuvilex owns the exclusive worldwide rights to use the Cell-in-a-Box
technology to develop treatments for any type of cancer and for
treatments for diabetes as well. The technology has already shown
equally amazing results in animal studies in both breast cancer and
diabetes. So, it doesn't stop at pancreatic cancer for Nuvilex or any
investor with a position in the company's stock, and that includes
Lincoln Park Capital.  
About Stock Market Media Group 
 SMMG is a full service IR firm
specializing in Research and Content Development. It offers a
platform for corporate stories to unfold through the media with
Reports, Interviews and Articles. For more information and to read
disclaimers and disclosures: 
Stock Market Media Group 
Press spacebar to pause and continue. Press esc to stop.